Table 1

Characteristics of the 78 patients with pSS enrolled in the AIR registry

Clinical data
 Age, years59.8 (29–83)
 Sex, women67 (86%)
 Disease duration, years11.9 (3–32)
Laboratory data
 No anti-SSA24 (31%)
 Anti-SSA alone34 (44%)
 Anti-SSA+anti-SSB20 (25%)
Rituximab regimen
 1 g×2, n (%)67 (86%)
 375 mg/m2×4, n (%)11 (14%)
Previous treatments
 Corticosteroids66 (85%)
 Hydroxychloroquine44 (56%)
 Methotrexate33 (42%)
 Azathioprine19 (24%)
 Leflunomide8 (10%)
 Intravenous immunoglobulin3 (4%)
 Plasmatic exchanges3 (4%)
Concomitant immunosuppressants
 Corticosteroids7 (9%)
 Hydroxychloroquine7 (9%)
 Methotrexate7 (9%)
 Azathioprine1 (1%)
 Mycophenolate mofetil1 (1%)
 Cyclophosphamide1 (1%)
  • Results are expressed as n (%).

  • AIR, AutoImmune and Rituximab registry; pSS, primary Sjögren's syndrome.